<DOC>
	<DOCNO>NCT02787551</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority insulin glargine/lixisenatide fix ratio combination ( FRC ) versus GLP-1 receptor agonist ( GLP-1 RA ) hemoglobin A1c ( HbA1c ) change . Secondary Objectives : To compare overall efficacy safety insulin glargine/lixisenatide fix ratio combination ( FRC ) GLP-1 receptor agonist ( GLP-1 RA ) top metformin ( without pioglitazone ) patient type 2 diabetes . To evaluate safety , efficacy endpoint FRC end extension period .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine/Lixisenatide Fixed Ratio Combination ( FRC ) Versus GLP-1 Receptor Agonist Patients With Type 2 Diabetes , With FRC Extension Period</brief_title>
	<detailed_description>The maximum duration GLP1-RA patient approximately 29 week : 2 week screening period , 26 week treatment period ( either randomize uncontrolled ) , 3 9 day post-treatment safety followup period . Maximum duration FRC patient approximately 55 week : 2- week screen period , 26-week randomized treatment period , 26-week extension period 3-day post-treatment safety follow-up period . All primary secondary efficacy , safety endpoint also assess end extension period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus diagnose least 1 year prior screen visit . Patients treat one follow glucagonlike peptide 1 ( GLP1 ) receptor agonist least 4 month prior screen visit ( V1 ) , stable dose least 3 month prior screen visit ( V1 ) : Liraglutide ( Victoza® ) 1.8 mg QD 1.2 mg QD , 1.8 mg QD dose well tolerated accord Investigator 's judgment Exenatide ( Byetta® ) 10 µg BID 5 µg BID , 10 µg BID dose well tolerated accord Investigator 's judgment combination metformin ( daily dose ≥1500 mg/day maximum tolerate dose [ MTD ] ) , without pioglitazone , stable dose least 3 month prior screen . Patients treat stable dose one follow GLP1 receptor agonist least 6 month prior screen visit ( V1 ) : Exenatide extendedrelease ( Bydureon® ) 2 mg weekly ( QW ) , well tolerate accord Investigator 's judgment , Albiglutide ( Tanzeum® ) 50 mg QW 30 mg QW , 50 mg QW well tolerate accord Investigator 's judgment , Dulaglutide ( Trulicity® ) 1.5 mg QW 0.75 mg QW , 1.5 mg QW well tolerate accord Investigator 's judgment combination metformin ( daily dose ≥1500 mg/day MTD ) , without pioglitazone , stable dose least 3 month prior screen ; Signed write informed consent . Exclusion criterion : At screen visit , age &lt; 18 . Screening HbA1c &lt; 7 % &gt; 9 % . Pregnancy lactation , woman childbearing potential effective contraceptive method . Any use antidiabetic drug within 3 month prior screen visit describe inclusion criterion . Previous treatment insulin year prior screen visit ( note : shortterm treatment insulin [ ≤10 day ] due intercurrent illness include gestational diabetes allow discretion study physician ) . Laboratory finding time screening , include : Fasting plasma glucose ( FPG ) &gt; 250 mg/dL ( 13.9 mmol/L ) , Amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) , Alanine transaminase aspartate transaminase &gt; 3 ULN , Calcitonin ≥20 pg/mL ( 5.9 pmol/L ) , Positive pregnancy test . Patient renal function impairment estimate glomerular filtration rate &lt; 30 mL/min ( use Modification Diet Renal Disease formula ) endstage renal disease . Contraindication use insulin glargine , lixisenatide GLP1 receptor agonist ( Victoza® , Byetta® , Bydureon® , Tanzeum® Trulicity® ) accord local labeling . Any contraindication metformin pioglitazone use , accord local labeling . History hypersensitivity insulin glargine , excipients . History allergic reaction GLP1 receptor agonist metacresol . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( eg , multiple endocrine neoplasia type 2 syndrome ) . History pancreatitis ( unless pancreatitis relate gallstone cholecystectomy already perform ) , chronic pancreatitis , pancreatitis previous treatment incretin therapy , pancreatectomy . Body mass index ≤20 &gt; 40 kg/m^2 Exclusion criterion extension period : Patients FRC arm rescue therapy HbA1c &gt; 8 % week 22 . Patients FRC arm discontinue prematurely FRC treatment week 26 . Patients GLP1RA treatment arm randomization . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>